4 結果
Fabry disease screening study in patients diagnosed with gastrointestinal tract (GIT) disease, i.e. with the diagnosis of non-infectious inflammatory bowel disease, functional dyspepsia or irritable bowel syndrome in particular, is a project designed as a pilot study of Centre for Fabry disease,
Healthy subjects will be randomized within one of the following sequential dose cohorts:
- LMN-101, six 500-mg capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7); or
- LMN-101, two 500-mg capsules and four 500-mg placebo capsules orally three times daily for
Hemolytic uremic syndrome (HUS) is defined by the combination of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The underlying lesion is thrombotic microangiopathy (TMA) affecting arteriole and capillary walls, with endothelial cells swelling and detachment and thrombi
OBJECTIVES
Objective 1 will test if dietary ganglioside treatment improves intestinal integrity, permeability and systemic inflammation in patients with inflammatory bowel disease (IBD).
Objective 2 will study the bioavailability of dietary ganglioside
BACKGROUND & SCOPE
This is a pilot study being